KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.

Cynthia J Tifft, Isabela Batsu, Roberto Giugliani, Harmonie Goyeau, Andreas Hahn, Simon A Jones, Pascal Minini, Ichiro Nakashima, Mar O'Callaghan, Susan Perlman, Nathan Thibault, Madhurima Uppara Kowthalam, Riliang Zheng, Timothy M Cox

Genet Med 28(1) 101615

PMID41108138
PMCID-
DOI10.1016/j.gim.2025.101615
发表日期2025-10-18
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: To evaluate efficacy and safety of venglustat for GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases) and cognate diseases. METHODS: The AMETHIST phase 3, randomized, double-blind, placebo-controlled study evaluated oral venglustat (N = 40) vs placebo (N = 19) in adults with late-onset GM2 gangliosidoses. Coprimary endpoints were annual percent change on the 9-Hole Peg Test and percent change in cerebrospinal fluid (CSF) GM2 ganglioside from baseline to week 104. A secondary population of participants with cognate diseases (N = 16) received open-label venglustat in a "basket" trial. RESULTS: CSF GM2 decreased by 47.6% (90% CI: -52.6, -42.6) with venglustat versus 11.3% (90% CI: -18.3, -4.4) with placebo (difference: -36.2 [90% CI: -44.8, -27.7], P < .0001). The annual percent change in 9-Hole Peg Test was 2.49% (90% CI: 0.28, 4.74) with venglustat versus 0.95% (90% CI: -2.16, 4.15) with placebo (difference: 1.54% [90% CI: -2.33, 5.39], P = .74). Decreased CSF GM2 concentrations did not correlate with clinical endpoints. Secondary population participants remained clinically stable. The most common adverse events were fall, headache, and contusion with placebo and fall, and COVID-19 and headache with venglustat. CONCLUSION: In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed. No new safety findings were observed.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。